Lead Time and Overdiagnosis
Authors:
Open Access
- 7 October 2014
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (12) , dju346
Abstract
In this issue of the Journal, Etzioni et al. ( 1 ) suggest a novel approach to estimating overdiagnosis in breast cancer. However, there is a key assumption in their method regarding the nature of overdiagnosis that is unlikely to hold and leads to an underestimate of the overdiagnosis rate. To understand this assumption, we need to go back to basic definitions. Lead time is the time from detection of preclinical cancer by screening to detection of clinical (symptomatic) cancer in the absence of screening. An overdiagnosed cancer is a cancer detected by screening that would not have presented clinically during that person’s lifetime in the absence of screening.Keywords
This publication has 9 references indexed in Scilit:
- A Reality Check for Overdiagnosis Estimates Associated With Breast Cancer ScreeningJNCI: Journal of the National Cancer Institute, 2014
- Recognizing Paradigm Instability in Theories of CarcinogenesisBritish Journal of Medicine and Medical Research, 2014
- Effect of Three Decades of Screening Mammography on Breast-Cancer IncidenceNew England Journal of Medicine, 2012
- Overdiagnosis in CancerJNCI: Journal of the National Cancer Institute, 2010
- Spontaneous “healing” of breast cancerBreast Cancer, 2005
- Issues in the mortality analysis of randomized controlled trials of cancer screeningControlled Clinical Trials, 1994
- Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.BMJ, 1988
- Simplified Models of Screening for Chronic Disease: Estimation Procedures from Mass Screening ProgrammesBiometrics, 1984
- On the theory of screening for chronic diseasesBiometrika, 1969